Form 10-Q · Quarterly report
Biogen 10-Q, filed Oct 28, 2026
- Filed
- CIK
- 0000875045
- Accession no.
- 0000875045-26-000096
Summary
Biogen completed its acquisition of Apellis on May 14, 2026, adding SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G, and primary IC-MPGN, and expects continued revenue declines for TECFIDERA and TYSABRI amid generic and biosimilar competition. Biogen also described U.S. tariff changes, including a February 2026 Supreme Court ruling striking down IEEPA tariffs and a 100% tariff on imports of patented pharmaceuticals and biologics imposed after a Section 232 investigation.
Key points
- Biogen completed the acquisition of Apellis on May 14, 2026, acquiring SYFOVRE for geographic atrophy and EMPAVELI for PNH, C3G, and primary IC-MPGN.
- The European Patent Office revoked Biogen's EP 2 653 873 patent for TECFIDERA in November 2025, and multiple generic entrants are now in North America, Brazil, and the EU.
- In February 2026 the U.S. Supreme Court struck down tariffs previously imposed under IEEPA, and Biogen has not recorded a receivable for any refund.
- After a Section 232 investigation, the U.S. Administration imposed a 100% tariff on imports of patented pharmaceuticals, biologics, and associated ingredients, effective for certain categories on July 31, 2026, and others on September 29, 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
ITEM 2. MANAGEMENT'S DISCUSSION EXECUTIVE SUMMARY INTRODUCTION Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We are focused on advancing our pipeline, including significant late stage programs, in neurology, specialized immunology and rare diseases across multiple modalities. Our drug discovery and development efforts are supported by internal research and development programs, external collaborations and acquisitions of businesses and assets. Our marketed products include VUMERITY, TYSABRI, TECFIDERA, AVONEX and PLEGRIDY for the treatment of MS; …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.